AU2001287801A1 - Acid-sensitive compounds, preparation and uses thereof - Google Patents
Acid-sensitive compounds, preparation and uses thereofInfo
- Publication number
- AU2001287801A1 AU2001287801A1 AU2001287801A AU8780101A AU2001287801A1 AU 2001287801 A1 AU2001287801 A1 AU 2001287801A1 AU 2001287801 A AU2001287801 A AU 2001287801A AU 8780101 A AU8780101 A AU 8780101A AU 2001287801 A1 AU2001287801 A1 AU 2001287801A1
- Authority
- AU
- Australia
- Prior art keywords
- acid
- sensitive
- compounds
- acidic
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Polyethers (AREA)
Abstract
Novel acid-sensitive compounds comprising at least one hydrophilic substituent and a cyclic ortho-ester which is acid-sensitive, and their salts. These compounds are useful for forming conjugates (liposomes, complexes, nanoparticles and the like) with biologically active substances and releasing them into cellular tissues or compartments whose pH is acidic, or as nonionic surfactant for stabilizing particles encapsulating a biologically active substance and then destabilizing them in acid medium, or alternatively as a vector covalently linked to a therapeutic molecule so as to release said therapeutic molecule into the cellular tissues or compartments whose pH is acidic.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0011278A FR2813605B1 (en) | 2000-09-05 | 2000-09-05 | ACIDOSENSITIVE COMPOUNDS, THEIR PREPARATION AND USES |
FR0011278 | 2000-09-05 | ||
US23911600P | 2000-10-11 | 2000-10-11 | |
US60239116 | 2000-10-11 | ||
PCT/FR2001/002725 WO2002020510A1 (en) | 2000-09-05 | 2001-09-03 | Acid-sensitive compounds, preparation and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001287801A1 true AU2001287801A1 (en) | 2002-03-22 |
Family
ID=26212598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001287801A Abandoned AU2001287801A1 (en) | 2000-09-05 | 2001-09-03 | Acid-sensitive compounds, preparation and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050085426A1 (en) |
EP (1) | EP1317439B1 (en) |
JP (1) | JP2004508364A (en) |
KR (1) | KR20030040441A (en) |
CN (1) | CN1452617A (en) |
AT (1) | ATE312088T1 (en) |
AU (1) | AU2001287801A1 (en) |
CA (1) | CA2421179A1 (en) |
DE (1) | DE60115667T2 (en) |
HU (1) | HUP0303379A3 (en) |
IL (1) | IL154736A0 (en) |
MX (1) | MXPA03001876A (en) |
WO (1) | WO2002020510A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338789T3 (en) | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | MACROCICLIC ANTAGONISTS OF THE MOTILINA RECEPTOR. |
FR2925491B1 (en) * | 2007-12-19 | 2010-09-03 | Oz Biosciences Sas | NEW CLASSES OF CATIONIC LIPIDS FOR THE TRANSPORT OF ACTIVE AGENTS IN CELLS |
KR101014246B1 (en) | 2008-07-03 | 2011-02-16 | 포항공과대학교 산학협력단 | pH SENSITIVE METAL NONAPARTICLES AND MANUFACTURING MEHTODS THEREOF |
GB201307438D0 (en) * | 2013-04-25 | 2013-06-05 | Airbus Uk Ltd | Fuel Additive |
KR101725240B1 (en) | 2015-03-24 | 2017-04-11 | 부산대학교 산학협력단 | DUAL STIMULI-RESPONSIVE CORE-SHELL MAGNETIC NANOPARTICLE HAVING UV-LIGHT RESPONSIVITY AND pH-RESPONSIVITY, AND DRUG DELIVERY COMPISING THE SAME |
EP3095790A1 (en) | 2015-05-22 | 2016-11-23 | Universite De Bordeaux | Nucleoside-lipid compounds with ph-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent |
US10822323B2 (en) * | 2018-02-26 | 2020-11-03 | Waters Technologies Corporation | Acid labile surfactants |
CN116656706A (en) * | 2023-04-18 | 2023-08-29 | 河南中医药大学第一附属医院 | Recombinant plasmid of acid-sensitive fusion protein and construction and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4406686A (en) * | 1981-07-24 | 1983-09-27 | Stauffer Chemical Company | Haloalkylaminomethyldioxolane herbicide antidotes |
FR2722506B1 (en) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES |
-
2001
- 2001-09-03 DE DE60115667T patent/DE60115667T2/en not_active Expired - Lifetime
- 2001-09-03 MX MXPA03001876A patent/MXPA03001876A/en unknown
- 2001-09-03 IL IL15473601A patent/IL154736A0/en unknown
- 2001-09-03 AU AU2001287801A patent/AU2001287801A1/en not_active Abandoned
- 2001-09-03 WO PCT/FR2001/002725 patent/WO2002020510A1/en active IP Right Grant
- 2001-09-03 AT AT01967418T patent/ATE312088T1/en not_active IP Right Cessation
- 2001-09-03 CN CN01815200A patent/CN1452617A/en active Pending
- 2001-09-03 CA CA002421179A patent/CA2421179A1/en not_active Abandoned
- 2001-09-03 EP EP01967418A patent/EP1317439B1/en not_active Expired - Lifetime
- 2001-09-03 KR KR10-2003-7003237A patent/KR20030040441A/en not_active Application Discontinuation
- 2001-09-03 US US10/129,262 patent/US20050085426A1/en not_active Abandoned
- 2001-09-03 JP JP2002525131A patent/JP2004508364A/en not_active Withdrawn
- 2001-09-03 HU HU0303379A patent/HUP0303379A3/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL154736A0 (en) | 2003-10-31 |
EP1317439A1 (en) | 2003-06-11 |
HUP0303379A2 (en) | 2004-01-28 |
HUP0303379A3 (en) | 2004-03-01 |
CN1452617A (en) | 2003-10-29 |
DE60115667D1 (en) | 2006-01-12 |
CA2421179A1 (en) | 2002-03-14 |
JP2004508364A (en) | 2004-03-18 |
WO2002020510A1 (en) | 2002-03-14 |
KR20030040441A (en) | 2003-05-22 |
US20050085426A1 (en) | 2005-04-21 |
MXPA03001876A (en) | 2004-09-10 |
EP1317439B1 (en) | 2005-12-07 |
DE60115667T2 (en) | 2006-08-24 |
ATE312088T1 (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Metal-organic frameworks for stimuli-responsive drug delivery | |
Xie et al. | O2-Cu/ZIF-8@ Ce6/ZIF-8@ F127 composite as a tumor microenvironment-responsive nanoplatform with enhanced photo-/chemodynamic antitumor efficacy | |
Kim et al. | Glutathione‐induced intracellular release of guests from mesoporous silica nanocontainers with cyclodextrin gatekeepers | |
BR0009176A (en) | Granular particle, dosage form, method for preparing a granular particle, dry mixtures, and granular formulation | |
BR0008590A (en) | Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed | |
NZ506241A (en) | Solid cyclodextrin flavor delivery systems | |
TW200727903A (en) | Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate | |
RU2008112146A (en) | COMPOSITIONS AND METHODS FOR PRODUCING MEDICINAL PRODUCTS Slightly Soluble in Water with Increased Stability | |
HK1064295A1 (en) | Medical aerosol formulations | |
WO2001035932A3 (en) | Sustained drug delivery from structural matrices | |
CA2468916A1 (en) | A stable oxaliplatin solution formulation | |
CN103563983A (en) | Nano-silver peroxide composite antibacterial solution and preparation method thereof | |
WO2003035051A3 (en) | The use of proton sequestering agents in drug formulations | |
AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
ECSP066663A (en) | VINFLUNINE PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION, PREPARATION PROCESS AND ITS USE | |
Tazina et al. | Specific features of drug encapsulation in liposomes (A review) | |
AU2001287801A1 (en) | Acid-sensitive compounds, preparation and uses thereof | |
Oommen et al. | Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system | |
MXPA05014232A (en) | Stable 5, 10-methylene-tetrahydrofolate pharmaceutical compounds. | |
Wang et al. | Carborane based mesoporous nanoparticles as a potential agent for BNCT | |
WO2002038126A3 (en) | A process for production of particles for pharmaceutical compositions having increased bioavailability | |
AU2003296602A1 (en) | Quaternary compounds comprising propolis as the active substance | |
Bally et al. | Novel procedures for generating and loading liposomal systems | |
CN108524942A (en) | A kind of pH responsive type medicine-carried nano particles and preparation method thereof based on ganoderma lucidum polysaccharide-histidine conjugate | |
Hosny | Anticancer and antimicrobial MOFs and their derived materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |